Literature DB >> 20339152

Poor clinical outcomes among pneumonia patients with schizophrenia.

Yi-Hua Chen1, Hsiu-Chen Lin, Herng-Ching Lin.   

Abstract

Despite the recent attention to patient safety and quality of care, no prior studies have addressed outcomes of hospitalization for pneumonia among patients with schizophrenia. This study investigated the extent to which clinical outcomes of pneumonia were different among patients with schizophrenia. This study used data from the Taiwan National Health Insurance Research Database. Of the total of 81,599 patients admitted with a principal diagnosis of pneumonia from 2002 to 2004, 949 had previously been admitted with a principal or secondary diagnosis of schizophrenia within the 2 years of their index pneumonia admission. We randomly selected 2847 pneumonia patients matched with the study group in terms of gender, age, year of admission, length of stay, and Charlson Comorbidity Index score as the comparison cohort. Conditional logistic regression models were used for analysis. Findings indicated a higher prevalence of adverse outcomes among patients with schizophrenia. Patients with schizophrenia were independently associated with a 1.81 times greater risk of intensive care unit admission (95% confidence interval [CI] = 1.37-2.40), a 1.37 times greater risk of acute respiratory failure (95% CI = 1.08-1.88), and a 1.34-fold greater risk of mechanical ventilation (95% CI = 1.04-1.92) after adjusting for characteristics of patients, physicians, hospitals, and potential clustering effects. Adjusted odds ratios were further evident among those treated in private hospitals and in regional/district hospitals. Significant barriers to prompt and appropriate medical care for pneumonia persist for patients with schizophrenia. Careful monitoring of physical health and proper integration between psychiatrists and physicians should be stressed to reduce poor clinical outcomes in this vulnerable population.

Entities:  

Mesh:

Year:  2010        PMID: 20339152      PMCID: PMC3160214          DOI: 10.1093/schbul/sbq019

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  35 in total

1.  Mortality among psychiatric patients in Taiwan--results from a universal National Health Insurance programme.

Authors:  Yi-Hua Chen; Hsin-Chien Lee; Herng-Ching Lin
Journal:  Psychiatry Res       Date:  2010-05-08       Impact factor: 3.222

2.  Medical morbidity, mental illness, and substance use disorders.

Authors:  Barbara Dickey; Sharon-Lise T Normand; Roger D Weiss; Robert E Drake; Hocine Azeni
Journal:  Psychiatr Serv       Date:  2002-07       Impact factor: 3.084

Review 3.  Schizophrenia.

Authors:  Robert Freedman
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

Review 4.  Medical illness in patients with schizophrenia.

Authors:  L S Goldman
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

5.  Smoking and mental illness: A population-based prevalence study.

Authors:  K Lasser; J W Boyd; S Woolhandler; D U Himmelstein; D McCormick; D H Bor
Journal:  JAMA       Date:  2000 Nov 22-29       Impact factor: 56.272

6.  Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina.

Authors:  C M Luna; A Famiglietti; R Absi; A J Videla; F J Nogueira; A D Fuenzalida; R J Gené
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

Review 7.  Optimizing treatment outcomes in severe community-acquired pneumonia.

Authors:  Felipe Rodríguez de Castro; Antoni Torres
Journal:  Am J Respir Med       Date:  2003

8.  Effect of a psychiatric diagnosis on nursing care for nonpsychiatric problems.

Authors:  Deborah Dillon McDonald; Michael Frakes; Beka Apostolidis; Brenda Armstrong; Stephen Goldblatt; Dawn Bernardo
Journal:  Res Nurs Health       Date:  2003-06       Impact factor: 2.228

Review 9.  Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers.

Authors:  Gavin D Barlow; Donna L Lamping; Peter G Davey; Dilip Nathwani
Journal:  Lancet Infect Dis       Date:  2003-08       Impact factor: 25.071

10.  Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998.

Authors:  David M Lawrence; Cashel D'arcy J Holman; Assen V Jablensky; Michael S T Hobbs
Journal:  Br J Psychiatry       Date:  2003-01       Impact factor: 9.319

View more
  15 in total

1.  Myoclonus as an indicator of infection in patients with schizophrenia treated with clozapine.

Authors:  Chih-Sung Liang; Ting-Hung Hsieh
Journal:  J Psychiatry Neurosci       Date:  2011-01       Impact factor: 6.186

2.  Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.

Authors:  Chian-Jue Kuo; Shu-Yu Yang; Ya-Tang Liao; Wei J Chen; Wen-Chung Lee; Wen-Yi Shau; Yao-Tung Chang; Shang-Ying Tsai; Chiao-Chicy Chen
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

3.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

4.  Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey.

Authors:  Carmen Moreno; Roberto Nuevo; Somnath Chatterji; Emese Verdes; Celso Arango; José Luis Ayuso-Mateos
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

5.  Non-psychiatric hospitalization length-of-stay for patients with psychotic disorders: A mixed methods study.

Authors:  Guy M Weissinger; J Margo Brooks Carthon; Bridgette M Brawner
Journal:  Gen Hosp Psychiatry       Date:  2020-07-31       Impact factor: 3.238

6.  Excess Mortality and Life-Years Lost in People With Schizophrenia and Other Non-affective Psychoses: An 11-Year Population-Based Cohort Study.

Authors:  Nicholas Chak Lam Yung; Corine Sau Man Wong; Joe Kwun Nam Chan; Eric Yu Hai Chen; Wing Chung Chang
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

7.  Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.

Authors:  Dieter Schoepf; Hardeep Uppal; Rahul Potluri; Reinhard Heun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-13       Impact factor: 5.270

8.  Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.

Authors:  Nancy H Liu; Gail L Daumit; Tarun Dua; Ralph Aquila; Fiona Charlson; Pim Cuijpers; Benjamin Druss; Kenn Dudek; Melvyn Freeman; Chiyo Fujii; Wolfgang Gaebel; Ulrich Hegerl; Itzhak Levav; Thomas Munk Laursen; Hong Ma; Mario Maj; Maria Elena Medina-Mora; Merete Nordentoft; Dorairaj Prabhakaran; Karen Pratt; Martin Prince; Thara Rangaswamy; David Shiers; Ezra Susser; Graham Thornicroft; Kristian Wahlbeck; Abe Fekadu Wassie; Harvey Whiteford; Shekhar Saxena
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

9.  Severe mental illness is associated with increased mortality and severe course of COVID-19.

Authors:  Carlo Alberto Barcella; Christoffer Polcwiartek; Grimur Høgnason Mohr; Gethin Hodges; Kathrine Søndergaard; Casper Niels Bang; Mikkel Porsborg Andersen; Emil Fosbøl; Lars Køber; Morten Schou; Christian Torp-Pedersen; Lars Vedel Kessing; Gunnar Gislason; Kristian Kragholm
Journal:  Acta Psychiatr Scand       Date:  2021-05-13       Impact factor: 7.734

10.  Cardiac complications associated with short-term mortality in schizophrenia patients hospitalized for pneumonia: a nationwide case-control study.

Authors:  Ya-Tang Liao; Shu-Yu Yang; Hsing-Cheng Liu; Wei J Chen; Chiao-Chicy Chen; Yen-Ni Hung; Chian-Jue Kuo
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.